作者
Arieh Berger,Elinor Gigi,Lana Kupershmidt,Zohar Meir,Nancy Gavert,Yaara Zwang,Amir Pri-Or,Shlomit Gilad,Uzi Harush,Izhak Haviv,Salomon M. Stemmer,Galia Blum,Emmanuelle Merquiol,Mariya Mardamshina,Sivan Kaminski Strauss,Gilgi Friedlander,Jair Bar,Iris Kamer,Yitzhak Reizel,Tamar Geiger,Yitzhak Pilpel,Yishai Levin,Amos Tanay,Baruch Barzel,Hadas Reuveni,Ravid Straussman
摘要
Stochastic transition of cancer cells between drug-sensitive and drug-tolerant persister phenotypes has been proposed to play a key role in non-genetic resistance to therapy. Yet, we show here that cancer cells actually possess a highly stable inherited chance to persist (CTP) during therapy. This CTP is non-stochastic, determined pre-treatment and has a unimodal distribution ranging from 0 to almost 100%. Notably, CTP is drug specific. We found that differential serine/threonine phosphorylation of the insulin receptor substrate 1 (IRS1) protein determines the CTP of lung and of head and neck cancer cells under epidermal growth factor receptor inhibition, both in vitro and in vivo. Indeed, the first-in-class IRS1 inhibitor NT219 was highly synergistic with anti-epidermal growth factor receptor therapy across multiple in vitro and in vivo models. Elucidation of drug-specific mechanisms that determine the degree and stability of cellular CTP may establish a framework for the elimination of cancer persisters, using new rationally designed drug combinations. Straussman and colleagues undertake clonal analyses and show that drug tolerance to EGFR therapy in lung cancer cell populations is an inherited continuous trait that is determined by IRS1 phosphorylation.